The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ethics Forum: The Ethical Considerations of Prior Authorization

Ethics Forum: The Ethical Considerations of Prior Authorization

September 17, 2020 • By Christina Schutt, DO, FAAP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The mother of a 15-year-old patient with juvenile idiopathic arthritis/enthesitis-related arthritis (JIA/ERA) called the office in tears. She said she was having an insurance problem.

You Might Also Like
  • Ethics Forum: Medical Ethical Considerations for COVID-19
  • Principles Would Streamline Prior Authorization Processes
  • Tips for Smoothing the Time-Consuming Prior Authorization Process
Explore This Issue
October 2020

Her son had been a star track athlete when he developed severe back pain. Magnetic resonance imaging showed evidence of severe sacroiliitis. He was started on a tumor necrosis factor inhibitor (TNFi) and promptly went into remission. He has been able to resume all activities without limitation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The mother recently changed insurance and received notice that her son’s TNFi would not be covered. The physician was not surprised and said the office would obtain prior authorization. Again, the medication was denied. The physician reached out for a peer-to-peer review, and the peer, a radiologist, reported the TNFi would not be authorized because the patient must have failed a conventional disease-modifying anti-rheumatic drug (DMARD) first.

The physician explained this was a continuation of current successful treatment; however, the physician was told the rules are the rules and no exception could be made. The physician escalated the prior authorization review to the medical director, who finally agreed to allow treatment with a TNFi, stating, however, that a different agent must be used because the prescribed treatment is not on formulary for the current insurance.

Dr. Christina Schutt

The physician reported back to the mother who remained worried her son will flare with a change in treatment and couldn’t understand why the physician was unable to convince the insurer to continue the current treatment.

This case illustrates a number of different ethical issues that are all too familiar to practicing physicians, who must balance trying to address the needs of one patient while responding to rules and changes that add time to a schedule already stretched thin.

Prior Authorization Struggles
Nothing is more frustrating or infuriating for a physician than spending time on hold with an insurance company to plead for approval so patients can obtain the medications they need, only to be met with cookie-cutter guidelines, forcing the physician to follow the guidelines or risk spending hours more on the phone. This is exceedingly common in pediatric rheumatology, in which many drugs are used off label, due to the difficulty of performing studies in the pediatric population.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Decisions often appear capricious. Companies may demand the use of a tablet in place of an expensive liquid despite the fact that the patient is a toddler. Companies may insist that all patients with any subtype of JIA be treated with a TNFi first, despite ample evidence that this class of medications does not work for systemic JIA. Patients who have been stable for years on one medication may be asked to switch to a different medication due to a sudden formulary change.

A practice of just three physicians would require one full-time employee to focus solely on prior authorizations.

This antiquated system forces physicians to make decisions about when a fight is worth the effort. Going through multiple appeals may take hours, while changing medications in response to insurance rules may cause patients to question the original treatment decision, interfering with the doctor-patient relationship.

Pages: 1 2 3 4 | Single Page

Filed Under: Ethics Tagged With: Committee on Ethics and Conflict of Interest, Ethics Forum, insurance, prior authorizationIssue: October 2020

You Might Also Like:
  • Ethics Forum: Medical Ethical Considerations for COVID-19
  • Principles Would Streamline Prior Authorization Processes
  • Tips for Smoothing the Time-Consuming Prior Authorization Process
  • Prior Authorization Struggle Continues

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)